NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC1+ or 2 - Fehrenbacher, L; Cecchini, R S; Geyer, C E, jr. (J Clin Oncol, 2020)